Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo | Latest News RSS feed

Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo - Latest News


Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

Bristol-Myers Squibb Co (NYSE:BMY) reported second-quarter earnings Thursday that topped Wall Street estimates on strong sales of its blockbuster cancer drug Opdivo and blood thinner Eliquis. For the ... read more

3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock

Bristol-Myers Squibb ... (what a drug is approved to treat). For instance, in October Bristol shares plunged nearly 19% due to a failure of one of its lung cancer drug's (Opdivo) late-stage ... read more

Multibillion-dollar cancer blockbusters boost drugmaker sales

Pfizer Inc., Merck & Co. and Bristol-Myers Squibb Co. all beat Wall Street's earnings projections in the first quarter, with sales of their ... The U.S. Food and Drug Administration also approved Opdi... read more

Looking for another news?


Merck profit beats, but Keytruda sales fail to impress

(Reuters) - Merck & Co (MRK.N) beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors w... read more


Bristol-Myers earnings jump 27 percent, but stock falls

Despite the beat, shares of Bristol-Myers declined in afternoon trading, while the broader markets were up, apparently because investors were disappointed by sales of its newest cancer drug, Opdivo .. ... read more

Keytruda Sales Power Merck to Quarterly Beat

(Reuters) - Drugmaker Merck & Co reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug ... pulled even with Bristo... read more

Bristol Myers Squibb kidney cancer treatment meets endpoint of late-stage trial

Bristol-Myers Squibb Co. (NYSE:BMY) has announced that a late-stage trial of its Opdivo and Yervoy drugs for treating a type of kidney cancer has met one of its main end-points. The trial showed patie... read more

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo Shares in Merck traded flat, slightly down to US$63.84 in premarket trade. “Strong commercia... read more

Bristol-Myers Squibb drops on surprise third quarter profits miss

Shares in Bristol Myers Squibb Co (NYSE ... Adjusted earnings per share for the quarter was 75 cents, below the consensus forecast of 77 cents. Strong sales of BMY’s Opdivo and Empliciti cancer drugs ... read more

Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

Bristol Myers-Squibb's immuno-oncology drug — Opdivo ... of its sales, has struggled to keep up with Merck's Keytruda. Meanwhile, Celgene has endured high-profile clinical failures and is looking for ... read more

New meds help drugmakers weather strong dollar, other issues

BRISTOL-MYERS SQUIBB ... its share price. Instead, investors were disappointed by the mere $40 million in sales of Bristol's newest melanoma drug, Opdivo, part of the hot new class of immunotherapy dr... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us